UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 1.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,341,063 shares of the company's stock after selling 36,454 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.29% of Teva Pharmaceutical Industries worth $73,637,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Oarsman Capital Inc. purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth $44,000. Ameliora Wealth Management Ltd. bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $66,000. IFP Advisors Inc increased its holdings in shares of Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after buying an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its position in shares of Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after buying an additional 949 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Up 2.4%

Teva Pharmaceutical Industries stock traded up $0.42 during mid-day trading on Wednesday, hitting $18.13. The company's stock had a trading volume of 11,474,751 shares, compared to its average volume of 10,030,686. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The company has a 50 day moving average of $15.47 and a 200-day moving average of $17.36. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The stock has a market cap of $20.56 billion, a PE ratio of -12.50, a P/E/G ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. During the same period in the previous year, the firm earned $0.48 earnings per share. The business's revenue was up 1.9% on a year-over-year basis. On average, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Bank of America raised their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Finally, Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday. They set a "buy" rating and a $25.00 price objective on the stock. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $24.50.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.